Compare $BCLI vs $PHIO | Chartloom

Compare

$BCLI vs $PHIO

Brainstorm Cell Therapeutics Inc · Phio Pharmaceuticals Corp

BCLI

Brainstorm Cell Therapeutics Inc

PHIO

Phio Pharmaceuticals Corp

Compare $BCLI vs $PHIO

Comparing Brainstorm Cell Therapeutics Inc and Phio Pharmaceuticals Corp

BCLIBrainstorm Cell Therapeutics Inc

PHIOPhio Pharmaceuticals Corp

BCLIBrainstorm Cell Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

54.9%

52W performance

30.1%

FCF yield

-21.1%

PHIOPhio Pharmaceuticals Corp

Market cap

$11M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-10.2%

52W performance

-59.6%

FCF yield

-107.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCLI

PHIO

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

PHIO

Phio Pharmaceuticals Corp

Market Cap

BCLI$10M

PHIO$11M

Enterprise Value

BCLI$12M

PHIO$-2M

Price

BCLI$0.95

PHIO$0.98

P/E Ratio

BCLIN/A

PHION/A

P/S Ratio

BCLI0.00x

PHIO81.74x

EV/Sales

BCLI0.00x

PHIO-11.08x

EV/EBITDA

BCLI0.00x

PHIO0.00x

P/B Ratio

BCLI7.31x

PHIO0.91x

P/FCF Ratio

BCLIN/A

PHION/A

EV/FCF

BCLI-5.29x

PHIO0.13x

PEG Ratio

BCLIN/A

PHION/A

Forward P/E (NTM)

BCLIN/A

PHION/A

Forward P/S (NTM)

BCLIN/A

PHION/A

Revenue (TTM)

BCLI$0

PHIO$0

Revenue Growth (YoY)

BCLIN/A

PHION/A

Forward Rev Growth

BCLI53.7%

PHIO0.0%

Gross Margin (TTM)

BCLI0.0%

PHIO0.0%

Operating Margin (TTM)

BCLI0.0%

PHIO0.0%

EBITDA Margin (TTM)

BCLI0.0%

PHIO0.0%

Net Margin (TTM)

BCLI0.0%

PHIO0.0%

FCF Margin (TTM)

BCLIN/A

PHION/A

Net Income (TTM)

BCLI$-7M

PHIO$-13M

FCF (TTM)

BCLI$-2M

PHIO$-12M

EPS (TTM)

BCLI-$0.61

PHIO-$1.11

ROE (TTM)

BCLI-23636.0%

PHIO-8741.0%

ROA (TTM)

BCLI-33822.0%

PHIO-7976.0%

ROIC (TTM)

BCLI-23636.0%

PHIO-8741.0%

Cash

BCLI$22K

PHIO$13M

Debt

BCLI$1M

PHIO$0

Net Cash/Debt

BCLI$-1M

PHIO$13M

Current Ratio (TTM)

BCLI0.21x

PHIO8.39x

Quick Ratio (TTM)

BCLI0.16x

PHIO7.62x

Debt/Equity (TTM)

BCLI0.00x

PHIO0.00x

Debt/Assets (TTM)

BCLI0.0%

PHIO0.0%

Interest Coverage (TTM)

BCLIN/A

PHION/A

Net Debt/EBITDA (TTM)

BCLI0.00x

PHIO0.00x

Beta

BCLI0.39

PHIO0.90

52W Performance

BCLI30.1%

PHIO-59.6%

YTD Performance

BCLI54.9%

PHIO-10.2%

% from 52W High

BCLI-43.8%

PHIO-76.6%

% from 52W Low

BCLI106.9%

PHIO20.8%

Asset Turnover (TTM)

BCLI0.00x

PHIO0.02x

FCF Yield (TTM)

BCLI-21.1%

PHIO-107.3%

Earnings Yield (TTM)

BCLI-64.2%

PHIO-113.5%

Dividend Yield (TTM)

BCLIN/A

PHION/A

Rule of 40

BCLI0.0

PHIO0.0

EV/GP/RG

BCLIN/A

PHION/A

Ticker research

View BCLI research View PHIO research

Metric	BCLI Brainstorm Cell Therapeutics Inc	PHIO Phio Pharmaceuticals Corp
Market & Valuation
Market Cap	$10M	$11M
Enterprise Value	$12M	$-2M
Price	$0.95	$0.98
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	81.74x
EV/Sales	0.00x	-11.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	0.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	0.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-7M	$-13M
FCF (TTM)	$-2M	$-12M
EPS (TTM)	-$0.61	-$1.11
ROE (TTM)	-23636.0%	-8741.0%
ROA (TTM)	-33822.0%	-7976.0%
ROIC (TTM)	-23636.0%	-8741.0%
Financial Health
Cash	$22K	$13M
Debt	$1M	$0
Net Cash/Debt	$-1M	$13M
Current Ratio (TTM)	0.21x	8.39x
Quick Ratio (TTM)	0.16x	7.62x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	0.90
52W Performance	30.1%	-59.6%
YTD Performance	54.9%	-10.2%
% from 52W High	-43.8%	-76.6%
% from 52W Low	106.9%	20.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-21.1%	-107.3%
Earnings Yield (TTM)	-64.2%	-113.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BCLI research	View PHIO research

Valuation

P/S Ratio

BCLI

0.00x

PHIO

81.74x

EV/FCF

BCLI

-5.29x

PHIO

0.13x

Growth & revenue

Forward Revenue Growth

BCLI

53.7%

PHIO

0.0%

Profitability & performance

Gross Margin

BCLI

0.0%

PHIO

0.0%

ROE

PHIO

-8741.0%

BCLI

-23636.0%

FCF Yield %

BCLI

-21.1%

PHIO

-107.3%

52-Week Performance

BCLI

30.1%

PHIO

-59.6%

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

PHIO

Phio Pharmaceuticals Corp

Market Cap

BCLI$10M

PHIO$11M

Enterprise Value

BCLI$12M

PHIO$-2M

Price

BCLI$0.95

PHIO$0.98

P/E Ratio

BCLIN/A

PHION/A

P/S Ratio

BCLI0.00x

PHIO81.74x

EV/Sales

BCLI0.00x

PHIO-11.08x

EV/EBITDA

BCLI0.00x

PHIO0.00x

P/B Ratio

BCLI7.31x

PHIO0.91x

P/FCF Ratio

BCLIN/A

PHION/A

EV/FCF

BCLI-5.29x

PHIO0.13x

PEG Ratio

BCLIN/A

PHION/A

Forward P/E (NTM)

BCLIN/A

PHION/A

Forward P/S (NTM)

BCLIN/A

PHION/A

Revenue (TTM)

BCLI$0

PHIO$0

Revenue Growth (YoY)

BCLIN/A

PHION/A

Forward Rev Growth

BCLI53.7%

PHIO0.0%

Gross Margin (TTM)

BCLI0.0%

PHIO0.0%

Operating Margin (TTM)

BCLI0.0%

PHIO0.0%

EBITDA Margin (TTM)

BCLI0.0%

PHIO0.0%

Net Margin (TTM)

BCLI0.0%

PHIO0.0%

FCF Margin (TTM)

BCLIN/A

PHION/A

Net Income (TTM)

BCLI$-7M

PHIO$-13M

FCF (TTM)

BCLI$-2M

PHIO$-12M

EPS (TTM)

BCLI-$0.61

PHIO-$1.11

ROE (TTM)

BCLI-23636.0%

PHIO-8741.0%

ROA (TTM)

BCLI-33822.0%

PHIO-7976.0%

ROIC (TTM)

BCLI-23636.0%

PHIO-8741.0%

Cash

BCLI$22K

PHIO$13M

Debt

BCLI$1M

PHIO$0

Net Cash/Debt

BCLI$-1M

PHIO$13M

Current Ratio (TTM)

BCLI0.21x

PHIO8.39x

Quick Ratio (TTM)

BCLI0.16x

PHIO7.62x

Debt/Equity (TTM)

BCLI0.00x

PHIO0.00x

Debt/Assets (TTM)

BCLI0.0%

PHIO0.0%

Interest Coverage (TTM)

BCLIN/A

PHION/A

Net Debt/EBITDA (TTM)

BCLI0.00x

PHIO0.00x

Beta

BCLI0.39

PHIO0.90

52W Performance

BCLI30.1%

PHIO-59.6%

YTD Performance

BCLI54.9%

PHIO-10.2%

% from 52W High

BCLI-43.8%

PHIO-76.6%

% from 52W Low

BCLI106.9%

PHIO20.8%

Asset Turnover (TTM)

BCLI0.00x

PHIO0.02x

FCF Yield (TTM)

BCLI-21.1%

PHIO-107.3%

Earnings Yield (TTM)

BCLI-64.2%

PHIO-113.5%

Dividend Yield (TTM)

BCLIN/A

PHION/A

Rule of 40

BCLI0.0

PHIO0.0

EV/GP/RG

BCLIN/A

PHION/A

Ticker research

View BCLI research View PHIO research

Metric	BCLI Brainstorm Cell Therapeutics Inc	PHIO Phio Pharmaceuticals Corp
Market & Valuation
Market Cap	$10M	$11M
Enterprise Value	$12M	$-2M
Price	$0.95	$0.98
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	81.74x
EV/Sales	0.00x	-11.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	0.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	0.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-7M	$-13M
FCF (TTM)	$-2M	$-12M
EPS (TTM)	-$0.61	-$1.11
ROE (TTM)	-23636.0%	-8741.0%
ROA (TTM)	-33822.0%	-7976.0%
ROIC (TTM)	-23636.0%	-8741.0%
Financial Health
Cash	$22K	$13M
Debt	$1M	$0
Net Cash/Debt	$-1M	$13M
Current Ratio (TTM)	0.21x	8.39x
Quick Ratio (TTM)	0.16x	7.62x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	0.90
52W Performance	30.1%	-59.6%
YTD Performance	54.9%	-10.2%
% from 52W High	-43.8%	-76.6%
% from 52W Low	106.9%	20.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-21.1%	-107.3%
Earnings Yield (TTM)	-64.2%	-113.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BCLI research	View PHIO research